Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review

Background: Carbapenems (ertapenem, imipenem, meropenem) are used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB), even if the published evidence is limited, particularly when it is otherwise difficult to identify the recommended four active drugs to be inclu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences Jg. 17; H. 3; S. 373
Hauptverfasser:	Sotgiu, Giovanni, D’Ambrosio, Lia, Centis, Rosella, Tiberi, Simon, Esposito, Susanna, Dore, Simone, Spanevello, Antonio, Migliori, Giovanni
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI 12.03.2016
Schlagworte:	Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use beta-Lactams - adverse effects beta-Lactams - therapeutic use Carbapenems - adverse effects Carbapenems - therapeutic use Clinical Studies as Topic Ertapenem Extensively Drug-Resistant Tuberculosis - drug therapy Humans Imipenem - adverse effects Imipenem - therapeutic use Meropenem Mycobacterium Review Thienamycins - adverse effects Thienamycins - therapeutic use Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy effectiveness imipenem safety tolerability meropenem MDR-TB carbapenems XDR-TB ertapenem
ISSN:	1422-0067, 1422-0067
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!